Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803500 | 1.00 | TDP1 (0.68) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL554957 | 1.00 | TDP1 (0.68) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL10482269 | 0.85 | TDP1 (0.50) | TDP1SLC1A3SLC1A2SLC1A1ADRA1A | |
| SCHEMBL28139615 | 0.84 | TDP1 (0.62) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL19690528 | 0.84 | TDP1 (0.62) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL28227487 | 0.83 | TDP1 (0.48) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL7375741 | 0.82 | TDP1 (0.59) | TDP1SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL17517216 | 0.82 | TDP1 (1.00) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL16925719 | 0.82 | TDP1 (1.00) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL22151 | 0.82 | TDP1 (1.00) | TDP1SMN1; SMN2SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-8883773-B2 | Cephem compound having pseudo-catechol group | SHIONOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| US-20130079319-A1 | CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079319-A1 | CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP | CENPE, CCNE2, CEP170 | TDP1 4361/4885SLC1A3 1131/4885SLC1A2 915/4885 |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | TDP1 2003/4885SLC1A3 4455/4885SLC1A2 4641/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | TDP1 1315/4885SLC1A3 1037/4885SLC1A2 1100/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | TDP1 4554/4885SLC1A3 1649/4885SLC1A2 1609/4885 |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | TDP1 2003/4885SLC1A3 4455/4885SLC1A2 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.